What is the Impact Factor of Human Psychopharmacology-Clinical and Experimental?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Human Psychopharmacology-Clinical and Experimental is 2.00, ranking in quartile Q3 of Web of Science (SCIE).

Is Human Psychopharmacology-Clinical and Experimental indexed in Web of Science or Scopus?

Yes, Human Psychopharmacology-Clinical and Experimental is indexed in Web of Science (SCIE, Q3 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.662 (Q2) and an H-index of 89.

Who publishes Human Psychopharmacology-Clinical and Experimental and what is the Article Processing Charge (APC)?

Human Psychopharmacology-Clinical and Experimental is published by John Wiley and Sons Ltd. The estimated Article Processing Charge (APC) is approximately $2,953 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Human Psychopharmacology-Clinical and Experimental?

The official ISO-4 abbreviation of Human Psychopharmacology-Clinical and Experimental is "HUM PSYCHOPHARM CLIN" with common acronym "hup". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q3Scopus Q2SCImago #8,809Hybrid

Human Psychopharmacology-Clinical and Experimental

Acronym:hup

•

Abbreviation (ISO):HUM PSYCHOPHARM CLIN

•

Identifier (ISSN):0885-6222(Print)/1099-1077(Online)

•

Publisher:John Wiley and Sons Ltd

Official Website Submission Portal Compare

Clarivate IF (2026)

2↑ +0.3

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Human Psychopharmacology-Clinical and Experimental

WoS Q3

Annual Impact Factor Metric

Current (2026):2

Scopus SJR & RankScopus Q2

0.662

#8,809

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

89 papers with at least that number of citations each

WoS: SCIE / JCRQ3

Self-Citation Rate0%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

47articles/year

53.13% Gold OA•78.26% Original Research

Aims & Scope

Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design

Topics Covered (Recognized by AI)

Medicine81.2%Psychology80.6%Biology73.6%Psychiatry68.5%Internal medicine60.5%Neuroscience47.7%Chemistry39.1%Endocrinology38.5%Pharmacology37.4%Biochemistry34.9%Computer science33.6%Pathology31.5%Genetics30.8%Receptor23.7%Anxiety22.2%Cognition20.7%Clinical psychology20.4%

Primary Research Areas

Rank68/93

IndexSCIE

Category	Index	Rank	Quartile
CLINICAL NEUROLOGY	JCRSCIE	188/296	Q3
PHARMACOLOGY & PHARMACY	JCRSCIE	249/356	Q3
PSYCHIATRY	JCRSCIE	181/293	Q3
PSYCHOLOGY	JCRSCIE	50/93	Q3
CLINICAL NEUROLOGY	JCISCIE	214/296	Q3
PHARMACOLOGY & PHARMACY	JCISCIE	239/356	Q3
PSYCHIATRY	JCISCIE	210/293	Q3
PSYCHOLOGY	JCISCIE	68/93	Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF2

Articles / Year41

Total Citations7

2025

IF1.7

Articles / Year37

Total Citations45

2024

IF1.8

Articles / Year35

Total Citations67

2023

IF1.7

Articles / Year34

Total Citations150

2022

IF2.13

Articles / Year38

Total Citations276

Year	Impact Factor	Articles / Year	Total Citations
2026	2	41	7
2025	1.7	37	45
2024	1.8	35	67
2023	1.7	34	150
2022	2.13	38	276
2021	1.672	60	501
2020	2.112	62	702
2019	2.265	44	474
2018	2.806	48	347
2017	—	85	2,211
2016	—	57	1,221
2015	—	73	1,821

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #8,809Scopus Q2SCImago Profile

Scopus Coverage:1986-2026

•

Scopus Broad Areas:MedicineNeuroscience

Scopus Citation Rank (SJR)Q2

0.662

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

1.89

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$2,953 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations208

3-Year Documents89

Citable Documents88

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate52.3%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Neurology (clinical)Q2

Pharmacology (medical)Q2

Psychiatry and Mental HealthQ2

NeurologyQ3

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

4区 (Zone 4)Medicine

Minor Category (Specific Field):

4区CLINICAL NEUROLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Human Psychopharmacology-Clinical and Experimental (acronym: hup, abbr: HUM PSYCHOPHARM CLIN, ISSN: 0885-6222) is a peer-reviewed international scholarly journal in the field of Medicine, published by John Wiley and Sons Ltd in England since 1986. The periodical holds a Journal Impact Factor (JIF) of 2.00, ranking in quartile Q3 of Web of Science (SCIE), a Scopus SJR indicator of 0.662 (Q2), an H-index of 89.

The journal enforces rigorous peer evaluation with a publication frequency of Bimonthly, an annual output of approximately 47 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $2,953 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.